TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
TSXV · COV.V · CAD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 07:50 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Covalon Technologies Ltd.’s next earnings report is currently expected on Dec 10, 2026, with estimated earnings per share of CA$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Covalon Technologies Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe, the Middle East, Asia, and Latin America, with licensing agreements in place. The company leverages three distinct proprietary technology platforms. Firstly, its collagen matrix platform underpins a family of products aimed at treating a variety of chronic and infected wounds, such as diabetic, pressure, and venous ulcers, as well as donor and graft sites, traumatic injuries healing by secondary intention, dehisced surgical wounds, and first- and second-degree burns. Secondly, an antimicrobial silicone adhesive platform is incorporated into pre- and post-surgical and vascular access products; these are specifically engineered to provide broad-spectrum antimicrobial protection by eliminating bacteria or yeast on contact. Thirdly, a unique medical coating platform employs a proprietary photo-polymerization process to generate active grafting sites, enabling the initiation and growth of new polymer chains directly on existing medical devices. Covalon's product portfolio, branded under "Covalon," encompasses advanced wound care dressings, surgical and peri-operative solutions, and infection management tools. These offerings reach a diverse clientele, including hospitals, specialized wound and burn centers, acute and long-term care facilities, home health care agencies, and physicians' offices, via a combination of direct sales and extensive third-party distribution networks.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | May 27, 2025 | CA$0.02+100.0% vs estimate | CA$7.59M-18.79% vs estimate |
|---|
| Q1 2025 | Feb 21, 2025 | CA$0.04+233.33% vs estimate | CA$8.17M+6.48% vs estimate |
|---|
| Q1 2025 | Jan 7, 2025 | CA$0.02-60.0% vs estimate | CA$8.87M-9.7% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CA$12.41+CA$2.74 (+28.34%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
$17.21-$0.15 (-0.86%)
Aurinia Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.6% below the high.
CA$0.04-CA$0.01 (-11.11%)
Medx Health Corp.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
CA$0.04CA$0.00 (0.0%)
Kane Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.0% below the high.
